ロード中...
Immunotargeting relapsed or refractory precursor B-cell acute lymphoblastic leukemia – role of blinatumomab
Patients with refractory or relapsed (R/R) acute lymphoblastic leukemia (ALL) have a dismal prognosis of around 5% long-term survival when treated with cytotoxic chemotherapy and allogenic stem cell transplantation. T-cell immunobased strategies open up new therapeutic perspectives. Blinatumomab is...
保存先:
| 出版年: | Onco Targets Ther |
|---|---|
| 主要な著者: | , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Dove Medical Press
2017
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5530848/ https://ncbi.nlm.nih.gov/pubmed/28790849 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S103470 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|